Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

CJEU rules no patent protection for human embryonic stem cell-related inventions: Brüstle v Greenpeace (IPEG) (ipwars.com) (EPLAW) (IPBiz) (Patent Baristas) (IP Whiteboard) (BIOtechNOW) (TechnoLlama)

US: FTC Issues FY 2011 patent settlement report; attempts to keep up the heat on passage of the Preserve Access to Affordable Generics Act (FDA Law Blog) (Patent Docs) (Patent Baristas)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

New WIPO-WHO drug R&D database for neglected disease licences (IP Watch)

UPOV sprouts a new public face – as farmers protest (IP Watch)

UPOV marks 50 years; breeders seek more enforcement, civil society wants in (IP Watch)

Shoot the phoenix, count the cost! – opinion on valuable patent life of a pharmaceutical product (The SPC Blog)

EU: CJEU rules no patent protection for human embryonic stem cell-related inventions: Brüstle v Greenpeace (IPEG) (ipwars.com) (EPLAW) (IPBiz) (Patent Baristas)

EU: CJEU says no to patents requiring the destruction of a human embryo – Brüstle v Greenpeace – an Australian perspective (IP Whiteboard)

EU: Stem cell patent decision hurts science – Brüstle v Greenpeace (BIOtechNOW)

EU: Technophobia as regulation – Brüstle v Greenpeace (TechnoLlama)

EU: Broccoli and tomatoes: it’s “green for stop, red for go!” – Cases G 2/07 and G 1/08 (IPKat)

US: FDA proposes to clarify and update orphan drug regulations (FDA Law Blog)

US: Sessions/Coburn Amendment to FDA Approps Bill seeks to effectively nullify AIA Section 37 ANGIOMAX PTE provision (FDA Law Blog)

US: FTC Issues FY 2011 patent settlement report; attempts to keep up the heat on passage of the Preserve Access to Affordable Generics Act (FDA Law Blog)

US: The FTC’s thinking does not make it so regarding reverse payment agreements (Patent Docs)

US: FTC study finds that pharmaceutical industry will cause world to explode (Patent Baristas)

US: Congress proposes to improve the device review process by amending the least burdensome and conflicts of interest provisions in the Act (FDA Law Blog)

US: Government prosecution for “on-label” discussions? Par files suit to stop government from expanding its reach (FDA Law Blog)

US: Preparing for Mayo v. Prometheus Labs (Patently-O)

US: Pioneer-DuPont sues Monsanto for infringing “low tech” agricultural biotechnology patents (Holman’s Biotech IP Blog)

 

Products

Arzerra (Ofatumumab) / Rituxan (Rituximab)– US: Claim construction ruling in Arzerra infringement case: Biogen Idec and Genentech v. GlaxoSmithKline (Holman’s Biotech IP Blog)

Femcon Fe (Norethindrone, Ethinyl estradiol) – US: Famy Care and Mylan settle Femcon Fe lawsuit with Warner Chilcott (Patent Circle)

Fentanyl – EU: Agreement over pain killer a tender issue in Europe (IP Whiteboard)

Quetiapine – Bulgaria: Quetiapine and Bulgaria’s transitional ruling: AstraZeneca v Bulgarian Patent Office (The SPC Blog)

Thalomid (Thalidomide, Mephalan, Prednisone) – Australia: APO: No extension for patent on drug ‘combination’ that is not a ‘mixture’: The Children’s Medical Center Corporation (Patentology)

Viagra (Sildenafil) – US: Viagra patent decision gives rise to dispute over ANDA approval, concern about 180-day exclusivity forfeiture; court rigidly applies patent statute: Pfizer v Teva (FDA Law Blog)